



Company Overview

Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RAR α agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with *RARA* gene overexpression.

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

Apr 9 2024, 7:00 AM EDT

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 2 2024, 4:30 PM EDT

Stock Overview

Symbol	SYRS
Exchange	Nasdaq
Market Cap	120.1m
Last Price	\$4.54
52-Week Range	\$2.0902 - \$8.17

04/19/2024 04:00 PM EDT

Investor Relations

Syros Pharmaceuticals
Karen Hunady
Director of Corporate
Communications & Investor
Relations
khunady@syros.com

Stern Investor Relations, Inc.
Hannah Deresiewicz
hannahd@sternir.com

Management Team

Conley Chee

President and Chief Executive Officer

Jason Haas

Chief Financial Officer

Gerald E. Quirk

Chief Legal Officer & Head of Business Development

Lisa Roberts

VP Human Resources

David A. Roth, M.D.

Chief Medical Officer

Kristin Stephens

Chief Development Officer

Syros Pharmaceuticals, Inc.

35 CambridgePark Drive
4th Floor
Cambridge, MA 02140

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.